UPDATE

The threat of Nipah virus : epidemiology, pathogenesis, and emerging therapies

Eskandar KIROLOS

Johannes Diakonie Klinik, Mosbach - Germany

Corresponding author :Email : kiroloss.eskandar@gmail.com submitted October 24, 2024 ; accepted December 10, 2024 ; published online Dcember 27, 2024

Citation: KIROLOS E. The threat of Nipah virus: epidemiology, pathogenesis, and emerging therapies (2024) J Fac Med Or 8 (2) : 1075-1082.

DOI : https://doi.org / 10.51782/jfmo.v8i2.248

KEY WORDS

Nipah virus, Zoonotic pathogens, Epidemiology, Vaccine development, Public health preparedness.

Abstract

Background. The Nipah virus (NiV) is an emerging zoonotic pathogen with a high fatality rate, posing significant global health risks due to its potential for widespread outbreaks. Originally identified in Malaysia in 1998, NiV has since caused multiple outbreaks in South and Southeast Asia, primarily transmitted through contact with infected bats or pigs and human-to-human transmission.

Main Body. This literature review provides a comprehensive examination of NiV, focusing on its epidemiology, pathogenesis, and clinical manifestations. The review discusses the challenges in early diagnosis, highlighting current diagnostic methods and recent advancements in rapid detection technologies. Therapeutic options remain limited, with supportive care being the primary management strategy; however, promising experimental treatments and ongoing clinical trials are explored. Vaccine development efforts are critically analyzed, underscoring the hurdles and potential candidates showing efficacy in preclinical studies. Public health preparedness and response strategies are evaluated, emphasizing the importance of international collaboration and lessons learned from previous outbreaks. Ethical and social considerations surrounding NiV outbreaks, including the impact on affected communities and communication strategies, are also addressed.

Conclusion. Given the high mortality rate and pandemic potential of NiV, continued research and investment in diagnostic, therapeutic, and preventive measures are crucial. This review highlights the urgent need for global health systems to enhance preparedness and response mechanisms to mitigate the threat posed by Nipah virus.

Introduction

The Nipah virus (NiV) is a highly pathogenic zoonotic virus that has garnered significant attention since its discovery due to its potential to cause severe disease in humans and animals. First identified during an outbreak in Malaysia in 1998, NiV was associated with severe encephalitis in humans and respiratory illness in pigs, leading to substantial economic and public health impacts [1]. The virus was named after the village of Kampung Sungai Nipah, where the initial outbreak was traced, highlighting the importance of geographic localization in its identification [1]. NiV belongs to the Paramyxoviridae family, genus Henipavirus, which also includes the Hendra virus, another notable zoonotic pathogen [2].

Geographically, NiV has a distinct distribution predominantly in South and Southeast Asia, with outbreaks reported in Malaysia, Singapore, Bangladesh, and India [3]. The initial Malaysian outbreak, which also affected neighboring Singapore, was primarily associated with pig farms, leading to a significant culling of livestock to control the spread [1]. Subsequent outbreaks in Bangladesh and India have demonstrated a different transmission dynamic, often linked to consumption of date palm sap contaminated by fruit bats, the natural reservoir of the virus [4]. These outbreaks have been characterized by person-to-person transmission, often within healthcare settings, underscoring the virus's ability to spread through direct contact with bodily fluids [5].

The primary reservoirs for NiV are fruit bats of the Pteropus genus, which harbor the virus asymptomatically and facilitate its transmission to intermediate hosts such as pigs or directly to humans [6]. The transmission dynamics of NiV are complex and involve multiple pathways. In the Malaysian context, the virus spread from bats to pigs and subsequently to humans through direct contact with infected pigs or their secretions [1]. In contrast, the Bangladeshi and Indian outbreaks highlighted the direct bat-to-human transmission via contaminated food sources, as well as human-to-human transmission, particularly in nosocomial settings [7]. This diversity in transmission routes complicates efforts to predict and control outbreaks, necessitating a multifaceted approach to surveillance and intervention strategies.

Methodology according PRISMA guidelines

This review was conducted following a systematic approach, adhering to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to ensure comprehensive coverage and transparency.

Research Questions

The primary research questions were :

1- What are the epidemiological characteristics of Nipah virus ?

2- What are the current diagnostic methods and emerging therapies for NiV?

3- What are the public health strategies for managing and preventing NiV outbreaks?

Search Strategy

A detailed search strategy was implemented across several reputable databases, including PubMed, Scopus, Google Scholar, and Web of Science. The following keywords were used: «Nipah virus,» «Zoonotic pathogens,» «Epidemiology,» «Vaccine development,» and «Public health preparedness.» Searches were conducted without language restrictions to include all relevant literature.

Eligibility Criteria

The eligibility criteria for selecting studies included :

1- Types of studies : peer-reviewed articles, systematic reviews, meta-analyses, randomized controlled trials (RCTs), cohort studies, case-control studies, and case series.

2- Population : studies focusing on human cases of NiV infection.

3- Interventions : diagnostic methods, therapeutic interventions, and public health strategies related to NiV.

4- Outcomes : epidemiological data, diagnostic accuracy, therapeutic efficacy, and effectiveness of public health interventions.

5- Study designs : Both qualitative and quantitative research designs were considered.

Search Protocol

The literature search covered publications from January 2000 to December 2023, ensuring a comprehensive review of the most recent and relevant studies. Studies published before 2000 were excluded unless they were seminal works. The search was updated in January 2024 to include the latest publications. There were no language restrictions, and non-English articles were translated using automated translation tools when necessary.

Study Selection

Two independent reviewers screened the titles and abstracts of all retrieved articles. Full texts of potentially relevant studies were then assessed for eligibility. Disagreements were resolved through discussion or by consulting a third reviewer. The study selection process is depicted in the PRISMA flow diagram (**Figure 1**).

Data Extraction

Data extraction was performed using a standardized form, capturing information on study characteristics (e.g., authors, publication year, country), population details, interventions, outcomes, and key findings. Extracted data were cross-checked by a second reviewer to ensure accuracy.

Quality Assessment

The quality of included studies was assessed using the Cochrane risk of bias tool for randomized trials and the Newcastle-Ottawa Scale for observational studies. The quality assessment focused on the study design, sample size, risk of bias, and applicability of findings to the research questions.

Figure 1 illustrates the PRISMA flow diagram



Epidemiology

Nipah virus (NiV) continues to pose a significant public health threat due to its high mortality rate and potential for widespread transmission. Recent outbreaks have reinforced the urgency of understanding its epidemiology. In May 2018, Kerala, India, witnessed an outbreak with 23 reported cases and 17 deaths, highlighting the virus's lethality and rapid spread in human populations [8]. This outbreak was linked to fruit bats, consistent with previous patterns observed in Bangladesh and Malaysia. Detailed case studies from this and other outbreaks underscore the variability in transmission dynamics, often influenced by local practices and ecological factors [9]. For instance, outbreaks in Bangladesh have frequently been associated with the consumption of raw date palm sap contaminated by bat excreta, a practice not prevalent in India or Malaysia [4].

The global spread of NiV, although currently limited to South and Southeast Asia, poses a significant concern due to the virus's potential for broader dissemination. The presence of Pteropus bats, the natural reservoir of NiV, across tropical and subtropical regions raises the possibility of future outbreaks in other parts of the world [5]. Human activities such as deforestation and urbanization increase interactions between bats and humans, facilitating spillover events [10]. The adaptability of NiV to different transmission routes, including direct human-to-human transmission, exacerbates the risk of wider spread. Recent modeling studies have indicated that international travel and trade could facilitate the spread of NiV beyond its current geographic confines if effective containment measures are not implemented [3].

Identifying and mitigating risk factors is crucial for controlling NiV outbreaks. Key risk factors include close contact with infected animals, consumption of contaminated food products, and lack of awareness about transmission modes. In Bangladesh, the collection and consumption of raw date palm sap have been repeatedly implicated in NiV transmission, leading to targeted public health interventions to modify this behavior [11]. Healthcare workers are particularly vulnerable due to the risk of nosocomial transmission, as seen in several outbreaks where secondary transmission occurred within hospital settings [8].

This underscores the need for stringent infection control practices and proper training for healthcare professionals. Furthermore, vulnerable populations such as children, the elderly, and those with comorbid conditions are at a higher risk of severe outcomes from NiV infection [4]. Addressing these vulnerabilities through targeted vaccination, if and when available, and public health education can significantly reduce the impact of future outbreaks.

Pathogenesis & clinical manifestations

Nipah virus (NiV) pathogenesis is complex, involving a multifaceted interaction between the virus and host cells, leading to severe disease manifestations. NiV is an RNA virus belonging to the Paramyxoviridae family, and its genome encodes six structural proteins essential for viral replication and pathogenesis [2]. The glycoproteins G and F facilitate viral entry by binding to the host cell receptors ephrin-B2 and ephrin-B3, which are highly expressed in endothelial and neuronal cells [12].

This receptor binding is critical for the widespread dissemination of the virus within the host, particularly affecting the central nervous system (CNS) and respiratory tract. Once inside the host cells, NiV exploits the cellular machinery for replication, leading to extensive cell damage and triggering a robust inflammatory response [13].

Clinically, NiV infection presents with a broad spectrum of symptoms, often progressing rapidly from mild to severe manifestations. Initial symptoms are nonspecific, including fever, headache, dizziness, and myalgia, which can resemble other febrile illnesses [9]. As the disease progresses, neurological symptoms such as encephalitis, characterized by altered mental status, seizures, and coma, become prominent due to the virus's neurotropism [13].

Respiratory involvement can also occur, manifesting as acute respiratory distress syndrome (ARDS), which complicates the clinical picture and contributes to the high fatality rate observed in NiV outbreaks [12]. The dual involvement of the CNS and respiratory systems underscores the severity of NiV infections and the need for prompt medical intervention.

Complications from NiV infection are severe and often fatal. The virus's propensity to cause encephalitis leads to significant neurological sequelae in survivors, including persistent cognitive deficits, motor dysfunction, and psychiatric disturbances [2].

Acute respiratory complications such as ARDS can result in hypoxemia, necessitating mechanical ventilation and intensive care support [9]. The overall mortality rate of NiV infection ranges from 40% to 75%, varying by outbreak and healthcare infrastructure [12].

Factors contributing to high mortality include delayed diagnosis, lack of effective antiviral treatments, and limited supportive care facilities, especially in resource-constrained settings [13]. The high mortality and morbidity associated with NiV highlight the critical need for improved diagnostic, therapeutic, and preventive measures to manage and mitigate the impact of future outbreaks.

Diagnostic approaches

Accurate and timely diagnosis of Nipah virus (NiV) infection is crucial for effective patient management and outbreak control. The primary diagnostic methods include reverse transcription polymerase chain reaction (RT-PCR) and serological assays. RT-PCR is the gold standard for NiV detection due to its high sensitivity and specificity, enabling the identification of viral RNA in various clinical specimens such as blood, cerebrospinal fluid, throat swabs, and urine [8]. This molecular technique allows for the early detection of NiV, which is essential for implementing timely isolation and treatment measures. Serological assays, including enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assay (IFA), are employed to detect NiV-specific antibodies, providing valuable information on past infections and aiding in epidemiological studies [2].

Despite the effectiveness of these diagnostic methods, several challenges hinder the early detection and diagnosis of NiV. One significant challenge is the non-specificity of initial clinical symptoms, which can resemble other febrile illnesses such as influenza and dengue, leading to misdiagnosis or delayed diagnosis [3]. Moreover, access to advanced diagnostic facilities is often limited in regions where NiV outbreaks occur, particularly in rural and resource-constrained settings.

This limitation necessitates the transportation of samples to centralized laboratories, which can delay diagnosis and impede prompt public health responses [11]. Additionally, the handling of NiV-infected samples requires biosafety level-4 (BSL-4) containment due to the virus's high pathogenicity, further complicating diagnostic efforts [9].

Recent advances in rapid diagnostic technologies offer promising solutions to these challenges. Point-of-care (POC) diagnostic tools, such as rapid antigen tests and portable PCR devices, have been developed to facilitate on-site testing, reducing the time from sample collection to result interpretation [13]. These technologies are designed to be user-friendly, enabling healthcare workers in remote areas to perform diagnostics without the need for sophisticated laboratory infrastructure.

Furthermore, advancements in nucleic acid amplification techniques, such as loop-mediated isothermal amplification (LAMP), provide rapid and accurate detection of NiV at lower costs and with less technical complexity compared to traditional RT-PCR [2]. The integration of these innovative diagnostic tools into existing healthcare systems can significantly enhance the early detection and management of NiV infections, ultimately improving outbreak response and control efforts.

Treatment & management

The treatment and management of Nipah virus (NiV) infection remain challenging due to the lack of specific antiviral therapies and vaccines. Current therapeutic options are primarily supportive, focusing on alleviating symptoms and managing complications. Ribavirin, a broad-spectrum antiviral, has been used empirically in some NiV outbreaks with variable success; however, its effectiveness against NiV remains inconclusive, and it is not specifically recommended for routine treatment [13].

Supportive care is essential for managing severe cases, particularly those involving neurological and respiratory complications. Intensive care measures, including mechanical ventilation for patients with acute respiratory distress syndrome (ARDS) and the management of seizures and other neurological symptoms, are critical components of supportive care [9]. Early recognition and aggressive supportive management are crucial to improving patient outcomes.

Experimental treatments and ongoing clinical trials are exploring novel therapeutic approaches to combat NiV infection. Monoclonal antibodies targeting the NiV glycoproteins have shown promise in preclinical studies and early-phase clinical trials. These antibodies aim to neutralize the virus and prevent its entry into host cells, thereby reducing viral load and disease severity [13]. Additionally, antiviral compounds such as remdesivir, which have been repurposed from other viral infections, are under investigation for their efficacy against NiV. Although data from animal models are promising, further clinical trials are necessary to establish their safety and effectiveness in humans [2]. The development of small interfering RNA (siRNA) therapies, which can specifically target and degrade viral RNA, is another area of active research, offering potential for targeted antiviral treatment [12].

Supportive care and management strategies play a pivotal role in the treatment of NiV-infected patients. Due to the high mortality rate associated with NiV, comprehensive care in a specialized setting is crucial. This includes vigilant monitoring of vital signs, maintenance of fluid and electrolyte balance, and prevention of secondary infections [9]. Neurological monitoring is particularly important, given the propensity of NiV to cause encephalitis. In resource-limited settings, the implementation of infection control measures to prevent nosocomial transmission is vital. This involves the use of personal protective equipment (PPE), isolation of infected patients, and strict adherence to hygiene protocols to protect healthcare workers and other patients [11]. Public health interventions, such as community education on avoiding exposure to potential reservoirs and implementing safe food practices, are also essential components of NiV management [3].

Vaccine development

The development of a vaccine for Nipah virus (NiV) has been a high priority in the field of infectious disease research, given the virus's high mortality rate and pandemic potential. Progress in vaccine research has been significant, with several promising candidates currently in various stages of development.

One of the leading approaches involves the use of recombinant viral vectors, such as the vesicular stomatitis virus (VSV) platform, which has shown strong immunogenicity and protective efficacy in preclinical trials [14]. Another notable candidate is the ChAdOx1 NiV vaccine, based on a chimpanzee adenovirus vector, which has demonstrated robust immune responses and protection in animal models [15]. These advances are promising steps towards an effective NiV vaccine.

Despite these promising developments, several challenges hinder the progress and deployment of NiV vaccines. One major challenge is the limited understanding of the correlates of protection for NiV, which complicates the evaluation of vaccine efficacy [13]. Additionally, the sporadic nature of NiV outbreaks poses difficulties in conducting large-scale clinical trials to assess vaccine efficacy in endemic regions. Ensuring the cold chain and logistical support for vaccine distribution in resource-limited settings where NiV outbreaks frequently occur is another significant hurdle [3]. Furthermore, gaining public trust and acceptance for vaccination programs, especially in rural areas with limited healthcare access, requires comprehensive community engagement and education efforts [12].

Promising vaccine candidates are currently advancing through preclinical and early-phase clinical trials. The HeV-sG recombinant subunit vaccine, which targets the NiV G glycoprotein, has shown promise in animal models and is progressing towards human trials [16]. Additionally, mRNA vaccine platforms, which have been successful in the rapid development of COVID-19 vaccines, are being explored for NiV. These platforms offer the advantages of rapid production and scalability, which are crucial for responding to emerging infectious diseases [2]. The future direction of NiV vaccine development will likely involve a combination of traditional and novel vaccine technologies, with an emphasis on achieving long-lasting immunity and ease of deployment in diverse settings.

Public health preparedness & response

Public health preparedness and response to Nipah virus (NiV) outbreaks necessitate comprehensive strategies to ensure effective containment and prevention. Key strategies include rapid identification and isolation of cases, contact tracing, and the implementation of infection control measures in healthcare settings [9]. Early detection through robust surveillance systems is crucial, as it enables prompt response actions to prevent the spread of the virus. Community education campaigns play a vital role in reducing risk behaviors, such as the consumption of raw date palm sap, which has been associated with NiV transmission in certain regions [11]. Vaccination, once available, will be a critical tool for long-term prevention and control of NiV outbreaks.

Public health organizations, both national and international, are pivotal in coordinating and supporting outbreak response efforts. The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) provide technical guidance, resources, and logistical support to affected countries [4]. These organizations also facilitate international collaborations for research, surveillance, and capacity building. For instance, the Coalition for Epidemic Preparedness Innovations (CEPI) has been instrumental in funding and accelerating the development of NiV vaccines and diagnostic tools [14]. Collaborative efforts between governments, non-governmental organizations (NGOs), and research institutions are essential to strengthen global health security against NiV and other emerging infectious diseases.

Lessons learned from past NiV outbreaks have significantly informed current and future preparedness plans. The 2018 outbreak in Kerala, India, demonstrated the effectiveness of rapid response teams and robust healthcare infrastructure in controlling an outbreak swiftly [8]. However, it also highlighted gaps in healthcare worker safety and the need for enhanced biosafety measures. Past experiences underscore the importance of timely risk communication, community engagement, and the integration of traditional and modern surveillance methods [3]. Future preparedness plans should focus on enhancing laboratory capacities, improving healthcare infrastructure in endemic regions, and ensuring the availability of critical supplies such as personal protective equipment (PPE) [12]. Additionally, fostering continuous international cooperation and funding for research and development is vital to address the evolving threat of NiV and to mitigate the risk of future pandemics.

Ethical & social considerations

The impact of Nipah virus (NiV) outbreaks on communities is profound, affecting not only the health of individuals but also the social and economic fabric of the affected regions. Outbreaks often lead to significant morbidity and mortality, instilling fear and stigma within communities [9]. The economic repercussions are substantial, as affected areas may experience trade restrictions, loss of income, and disruptions to daily life. Additionally, the psychological burden on survivors and families of victims can be considerable, necessitating comprehensive mental health support [13]. Understanding and addressing these impacts are critical to formulating effective public health responses that are sensitive to the needs and circumstances of affected populations.

Ethical dilemmas frequently arise in the treatment and quarantine measures during NiV outbreaks. The need for strict isolation and quarantine protocols to prevent the spread of the virus can conflict with individuals' rights to freedom and autonomy [3]. Healthcare workers face challenging decisions regarding the allocation of limited resources, such as intensive care beds and antiviral treatments, especially in resource-constrained settings [11]. Balancing the duty to treat with the risk of healthcare worker exposure to the virus presents another ethical challenge. Informed consent, transparency, and respect for patients' dignity are essential ethical principles that must guide decision-making processes during outbreaks [12].

Effective communication strategies and public awareness campaigns are vital components of managing NiV outbreaks. Clear, accurate, and timely information helps to mitigate panic and misinformation, which can exacerbate the spread of the virus and hinder control measures [2]. Public health authorities must engage with community leaders and use culturally appropriate methods to disseminate information about prevention practices, symptoms, and the importance of seeking medical care.

Addressing myths and misconceptions about the virus through targeted education campaigns can enhance community compliance with public health measures [4]. Furthermore, involving communities in the planning and implementation of response activities fosters trust and cooperation, which are essential for the successful containment of NiV outbreaks [16].

Future directions & research needs

Future directions in Nipah virus (NiV) research and management necessitate addressing significant gaps in current knowledge and establishing clear research priorities. One critical area of need is a deeper understanding of the virus's pathogenesis and transmission dynamics, particularly the mechanisms underlying its zoonotic spillover and human-to-human transmission [12]. Additionally, the identification of reliable correlates of protection is essential for the development and evaluation of effective vaccines and therapeutic interventions. Surveillance systems must be strengthened to detect and monitor NiV outbreaks promptly, especially in endemic regions where the virus circulates in animal reservoirs such as fruit bats [2].

Technological innovations and potential breakthroughs hold promise for advancing NiV research and response. The development of rapid diagnostic tools, such as point-of-care tests, can significantly improve early detection and containment efforts [13]. Advances in vaccine technology, including mRNA and viral vector platforms, offer new avenues for creating effective and scalable vaccines against NiV. Furthermore, innovations in antiviral drug development, such as small molecule inhibitors and monoclonal antibodies, are critical for expanding the therapeutic arsenal against NiV [14]. Enhanced data analytics and bioinformatics approaches can also provide valuable insights into NiV evolution and epidemiology, guiding targeted public health interventions [9].

Collaboration between scientific, medical, and public health communities is vital for addressing the multifaceted challenges posed by NiV. Multidisciplinary research initiatives that integrate virology, immunology, and epidemiology are essential for comprehensive understanding and management of NiV. International cooperation and data sharing, facilitated by organizations such as the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI), are crucial for coordinated global responses to NiV outbreaks [16].

Engaging local communities and healthcare workers in research and response efforts ensures that interventions are culturally appropriate and effectively implemented [4]. Strengthening these collaborative networks will enhance the capacity to respond to NiV and other emerging infectious diseases, ultimately contributing to global health security.

Conclusion

In conclusion, the Nipah virus presents a formidable challenge to global health due to its high mortality rate, potential for human-to-human transmission, and lack of specific treatments and vaccines. Advances in understanding the virus's pathogenesis, transmission dynamics, and host interactions have been significant, yet critical gaps remain. Recent outbreaks have underscored the importance of rapid diagnostic methods, effective therapeutic options, and robust public health strategies to contain and prevent further spread.

Collaborative efforts among the scientific, medical, and public health communities are essential to develop innovative technologies, enhance surveillance systems, and ensure comprehensive preparedness and response plans. Continued investment in research, public awareness, and international cooperation will be vital to mitigate the impact of NiV and safeguard global health security.

COMPETING INTERESTS

The authors declare that they have no competing interests

References

[1] Chua KB. Nipah virus outbreak in Malaysia. J Clin Virol. 2003 Apr;26(3):265-75. doi: 10.1016/s1386-6532(02)00268-8. PMID: 12637075.

[2] Clayton BA, Wang LF, Marsh GA. Henipaviruses: an updated review focusing on the pteropid reservoir and features of transmission. Zoonoses Public Health. 2013 Feb;60(1):69-83. doi: 10.1111/j.1863-2378.2012.01501.x. Epub 2012 Jun 18. PMID: 22709528.

[3] Lo MK, Rota PA. The emergence of Nipah virus, a highly pathogenic paramyxovirus. J Clin Virol. 2008 Dec;43(4):396-400. doi: 10.1016/j.jcv.2008.08.007. Epub 2008 Oct 2. PMID: 18835214.

[4] Rahman MA, Hossain MJ, Sultana S, Homaira N, Khan SU, Rahman M, Gurley ES, Rollin PE, Lo MK, Comer JA, Lowe L, Rota PA, Ksiazek TG, Kenah E, Sharker Y, Luby SP. Date palm sap linked to Nipah virus outbreak in Bangladesh, 2008. Vector Borne Zoonotic Dis. 2012 Jan;12(1):65-72. doi: 10.1089/vbz.2011.0656. Epub 2011 Sep 16. PMID: 21923274.

[5] Epstein JH, Field HE, Luby S, Pulliam JR, Daszak P. Nipah virus: impact, origins, and causes of emergence. Curr Infect Dis Rep. 2006 Jan;8(1):59-65. doi: 10.1007/s11908-006-0036-2. PMID: 16448602; PMCID: PMC7088631.

[6] Singh RK, Dhama K, Chakraborty S, Tiwari R, Natesan S, Khandia R, Munjal A, Vora KS, Latheef SK, Karthik K, Singh Malik Y, Singh R, Chaicumpa W, Mourya DT. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review. Vet Q. 2019 Dec;39(1):26-55. doi: 10.1080/01652176.2019.1580827. PMID: 31006350; PMCID: PMC6830995.

[7] Luby SP. The pandemic potential of Nipah virus. Antiviral Res. 2013 Oct;100(1):38-43. doi: 10.1016/j.antiviral.2013.07.011. Epub 2013 Jul 30. PMID: 23911335.

[8] Arunkumar G, Chandni R, Mourya DT, Singh SK, Sadanandan R, Sudan P, Bhargava B; Nipah Investigators People and Health Study Group. Outbreak Investigation of Nipah Virus Disease in Kerala, India, 2018. J Infect Dis. 2019 May 24;219(12):1867-1878. doi: 10.1093/infdis/jiy612. PMID: 30364984.

[9] Bruno L, Nappo MA, Ferrari L, Di Lecce R, Guarnieri C, Cantoni AM, Corradi A. Nipah virus disease: epidemiological, clinical, diagnostic and legislative aspects of this unpredictable emerging zoonosis. Animals. 2022;13(1):159. doi:10.3390/ani13010159

[10] Daszak P, Cunningham AA, Hyatt AD. Anthropogenic environmental change and the emergence of infectious diseases in wildlife. Acta Trop. 2001 Feb 23;78(2):103-16. doi: 10.1016/s0001-706x(00)00179-0. PMID: 11230820.

[11] Sazzad HM, Hossain MJ, Gurley ES, Ameen KM, Parveen S, Islam MS, Faruque LI, Podder G, Banu SS, Lo MK, Rollin PE, Rota PA, Daszak P, Rahman M, Luby SP. Nipah virus infection outbreak with nosocomial and corpse-to-human transmission, Bangladesh. Emerg Infect Dis. 2013 Feb;19(2):210-7. doi: 10.3201/eid1902.120971. PMID: 23347678; PMCID: PMC3559054.

[12] Talukdar P, Dutta D, Ghosh E, Bose I, Bhattacharjee S. Molecular Pathogenesis of Nipah Virus. Appl Biochem Biotechnol. 2023 Apr;195(4):2451-2462. doi: 10.1007/s12010-022-04300-0. Epub 2023 Jan 19. PMID: 36656534; PMCID: PMC9869300.

[13] Ang BSP, Lim TCC, Wang L. Nipah Virus Infection. J Clin Microbiol. 2018 May 25;56(6):e01875-17. doi: 10.1128/JCM.01875-17. PMID: 29643201; PMCID: PMC5971524.

[14] Johnson K, Vu M, Freiberg AN. Recent advances in combating Nipah virus. Fac Rev. 2021 Sep 29;10:74. doi: 10.12703/r/10-74. PMID: 34632460; PMCID: PMC8483238.

[15] van Doremalen N, Avanzato VA, Goldin K, Feldmann F, Schulz JE, Haddock E, Okumura A, Lovaglio J, Hanley PW, Cordova K, Saturday G, de Wit E, Lambe T, Gilbert SC, Munster VJ. ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys. NPJ Vaccines. 2022 Dec 21;7(1):171. doi: 10.1038/s41541-022-00592-9. PMID: 36543806; PMCID: PMC9768398.

[16] McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D, Feng YR, Broder CC, Wang LF, Bossart KN. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. Vaccine. 2008 Jul 23;26(31):3842-52. doi: 10.1016/j.vaccine.2008.05.016. Epub 2008 Jun 2. PMID: 18556094; PMCID: PMC6186147.